利伯氏先天性失明市場規模、佔有率和成長分析：按治療方法、目標基因變異、最終用戶和地區分類－2026-2033年產業預測

2024 年全球萊伯先天性全盲 (LCA) 市場價值為 11.8 億美元，預計到 2025 年將成長至 12.3 億美元，到 2033 年將成長至 17.6 億美元，在預測期（2026-2033 年）內複合年成長率為 4.6%。

全球先天性全盲症（LCA）市場正經歷著顯著的變革，這主要得益於創新療法、診斷方法和支持服務的不斷湧現，旨在應對這種罕見的遺傳性視網膜營養不良。兒童恢復視力的迫切需求正在擴大市場潛力，促使人們的焦點從依賴低視力輔助設備轉向前景廣闊的基因替代療法。基因替代載體的引入提升了投資者的興趣，並加速了對LCA研發的資金投入。監管獎勵也進一步推動了市場成長，例如孤兒藥認定和加速核准流程降低了財務風險，同時改善了病患的治療機會。此外，人工智慧驅動的基因治療方法正在催生更精細的治療策略、更高的安全性以及資金籌措。這不僅豐富了治療方案，也創造了對基因檢測和監測解決方案的需求。

全球萊伯氏先天性暗點市場成長要素

基因編輯技術的進步使得針對RPE65突變（萊伯氏先天性暗點的主要病因）的標靶修飾成為可能，並贏得了醫療專業人士和投資者的信任。隨著這些治療載體不斷發展，展現出更高的療效和安全性，醫療專業人士正擴大將這些創新療法應用於合格的患者。這項科學進步不僅吸引了研究經費，也促進了相關人員之間的合作，並顯著豐富了潛在療法的種類。因此，這種充滿活力的環境正在推動市場成長，提高全球根治性療法的可及性，並最終改善患者的生活品質。

萊伯先天性失明全球市場的限制因素

萊伯氏先天性暗點市場面臨許多限制因素，包括病毒載體生產和個人化基因編輯等複雜製造過程導致治療成本飆升。高昂的價格對支付方和醫療系統帶來挑戰，常常使報銷機制捉襟見肘，並延緩保險核准。因此，許多患者面臨經濟障礙，難以獲得這些創新療法。儘管臨床潛力巨大，但抑制了需求，阻礙了市場成長。此外，保險公司通常要求提供充分的臨床證據才能批准全額報銷，導致患者等待治療的時間延長，削弱了整體市場活力。

萊伯先天性失明全球市場趨勢

全球萊伯氏先天性暗點市場正經歷顯著的發展趨勢，這主要得益於腺結合病毒載體基因療法的日益普及。保險覆蓋範圍的擴大進一步推動了這一趨勢，使患者更容易獲得創新療法。隨著臨床醫生擴大將單劑量基因療法納入常規治療方案，患者對輔助設備的依賴性也隨之降低。同時，患者權益倡導組織進行的有效宣傳活動，促使患者更早確診並參與治療計畫。這些不斷變化的情況正在重塑醫療服務提供者的偏好，並促使製藥公司拓展產品線，最終創造一個更穩健的市場環境，從而更好地支持患者的持續治療。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

Lieber先天性全盲症的全球市場規模：依治療類型分類

• 基因治療
  • RPE65基因替代療法
  • 利用 CRISPR 進行基因編輯
  • AAV載體療法
• 藥物治療
  • 類視色素療法
  • 神經保護劑
  • 抗氧化療法
• 視網膜人工替代物和輔助設備
• 幹細胞療法
• 基於光遺傳學的治療方法

Lieber先天性全盲的全球市場規模：以標靶基因突變分類。

• CEP290
• RPE65
• GUCY2D
• 其他基因

利伯氏先天性全盲症的全球市場規模：依最終用戶分類

• 醫院
• 專科眼科診所
• 眼科研究中心

Lieber先天性全盲症的全球市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Spark Therapeutics, Inc.（F. Hoffmann-La Roche Ltd.）
• Novartis AG
• Editas Medicine, Inc.
• ProQR Therapeutics NV
• Atsena Therapeutics, Inc.
• MeiraGTx Holdings PLC
• Applied Genetic Technologies Corporation（AGTC）
• REGENXBIO Inc.
• Opus Genetics, Inc.
• GenKOre Biosciences
• Ocugen, Inc.
• Biogen Inc.
• Gilead Sciences, Inc.
• AbbVie Inc.
• Alcon Laboratories
• Bausch+Lomb（Bausch Health）
• Ophthea Limited
• Santen Pharmaceutical Co., Ltd.
• Regenxbio, Inc.

結論與建議

Global Leber Congenital Amaurosis Market size was valued at USD 1.18 Billion in 2024 and is poised to grow from USD 1.23 Billion in 2025 to USD 1.76 Billion by 2033, growing at a CAGR of 4.6% during the forecast period (2026-2033).

The global market for Leber Congenital Amaurosis (LCA) is evolving significantly, driven by innovative therapies, diagnostics, and support services addressing this rare inherited retinal dystrophy. The critical unmet medical need for restoring vision in affected infants has broadened the market's potential, transitioning from reliance on low-vision aids to promising gene-replacement therapies. The introduction of gene-replacement vectors has piqued the interest of investors, spurring capital allocation into LCA research and development. Regulatory incentives are further propelling market growth, as orphan-drug designations and expedited approvals reduce financial risks while enhancing patient access. Additionally, AI-driven approaches in gene therapy are refining treatment strategies, improving safety, and attracting funding, thus enriching the therapeutic pipeline and generating demand for genetic testing and monitoring solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Leber Congenital Amaurosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Leber Congenital Amaurosis Market Segments Analysis

Global leber congenital amaurosis market is segmented by treatment type, target gene mutation, end user and region. Based on treatment type, the market is segmented into Gene Therapy, Pharmacological Therapy, Retinal Prosthesis & Assistive Devices, Stem Cell Therapy and Optogenetics-Based Treatments. Based on target gene mutation, the market is segmented into CEP290, RPE65, GUCY2D and Other Genes. Based on end user, the market is segmented into Hospitals, Specialized Eye Clinics and Ophthalmology Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Leber Congenital Amaurosis Market

The advancement of gene editing technologies is facilitating the targeted correction of the RPE65 mutation, a leading cause of Leber congenital amaurosis, thereby enhancing trust among healthcare professionals and investors alike. As these therapeutic vectors continue to evolve, demonstrating greater efficacy and safety, medical practitioners are increasingly inclined to utilize these innovative treatments for suitable patients. This scientific progress not only attracts research funding but also fosters collaboration among stakeholders, significantly enriching the portfolio of potential therapies. Consequently, this dynamic environment drives market growth and enhances the global accessibility of curative options, ultimately improving the quality of life for those impacted.

Restraints in the Global Leber Congenital Amaurosis Market

The Leber Congenital Amaurosis market faces significant constraints due to the complex manufacturing processes associated with viral vector production and personalized gene editing, which drive up the costs of treatment. These high price points create challenges for payers and healthcare systems, often straining their reimbursement frameworks and resulting in postponed coverage decisions. As a result, many patients experience financial barriers that restrict their access to these innovative therapies, ultimately suppressing demand and hindering market growth despite the clinical potential. Furthermore, insurance companies frequently demand substantial clinical evidence before granting full reimbursement, prolonging patient wait times for treatment and diminishing overall market activity.

Market Trends of the Global Leber Congenital Amaurosis Market

The Global Leber Congenital Amaurosis market is witnessing a significant trend driven by the expanding adoption of gene therapy solutions, notably through the utilization of adeno-associated viral vectors. This shift is bolstered by enhanced insurance coverage, facilitating greater access to innovative treatments. As clinicians increasingly incorporate single-dose gene therapies into routine care regimens, a decline in dependency on supportive devices is observed. Concurrently, patient advocacy groups are effectively raising awareness, leading to earlier diagnoses and increased participation in therapeutic programs. This evolving landscape is reshaping provider preferences while prompting pharmaceutical companies to diversify their pipelines, ultimately creating a more robust market environment for sustained patient support.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Leber Congenital Amaurosis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Gene Therapy
  • RPE65 Gene Replacement
  • CRISPR-Based Gene Editing
  • AAV Vector Therapies
• Pharmacological Therapy
  • Retinoid-Based Therapies
  • Neuroprotective Agents
  • Antioxidant Therapies
• Retinal Prosthesis & Assistive Devices
• Stem Cell Therapy
• Optogenetics-Based Treatments

Global Leber Congenital Amaurosis Market Size by Target Gene Mutation & CAGR (2026-2033)

• Market Overview
• CEP290
• RPE65
• GUCY2D
• Other Genes

Global Leber Congenital Amaurosis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialized Eye Clinics
• Ophthalmology Research Centers

Global Leber Congenital Amaurosis Market Size & CAGR (2026-2033)

• North America (Treatment Type, Target Gene Mutation, End User)
  • US
  • Canada
• Europe (Treatment Type, Target Gene Mutation, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Target Gene Mutation, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Target Gene Mutation, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Target Gene Mutation, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProQR Therapeutics N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atsena Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Applied Genetic Technologies Corporation (AGTC)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opus Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenKOre Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Bausch Health)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ophthea Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regenxbio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations